Phase 2 Chronic Rhinosinusitis Trial, Completed NCT02403479 Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Condition: Chronic Rhinosinusitis
Back to Chronic Rhinosinusitis

Trial results

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to the results reported on ClinicalTrials.gov, this trial involved 22 people in total — 10 in one group and 12 in the other. It was a crossover study, meaning participants tried both treatments at different times: one group received saline (a saltwater rinse) first and then silver colloid (a liquid containing tiny silver particles), while the other group received them in the opposite order. The trial was measuring changes in two things over 12 weeks: a questionnaire score reflecting how much chronic rhinosinusitis (long-term sinus inflammation) affected quality of life, and a score from a camera examination of the sinuses. Of the 22 who started, 20 completed the trial — 2 people in the "saline first" group did not finish, and the data does not report why. The reported data shows the following numbers for the quality-of-life questionnaire (called the SNOT-22, scored 0–110, where higher scores mean more severe symptoms): at the start of the study, the "saline first" group averaged 59.3 and the "silver colloid first" group averaged 52.9. At the 6-week point, those averages were 45.4 and 51.8 respectively. At 12 weeks, they were 49.3 and 56.5. For the camera examination score (called the Lund-Kennedy score, ranging 0–24, where higher means more obstruction), the starting averages were 7.8 and 6.8. At 6 weeks they were 5.9 and 5.7, and at 12 weeks they were 4.8 and 4.7. The reported data does not include a statistical comparison between the two treatments, so no conclusion about any difference between them can be drawn from the figures alone. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

Phase 2 Chronic Rhinosinusitis Trial, Completed

NCT02403479
Completed Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have had at least 12 weeks of symptoms that include at least 2 of the following: a blocked nose, discharge from the nose or mucus dripping down the back of your throat, pain or pressure in your face, or a reduced sense of smell.
  • You have tried at least 2 treatments for your chronic sinus condition that did not work, such as: sinus surgery, antibiotic tablets matched to your specific infection, steroid tablets or sprays, nasal rinsing with diluted baby shampoo, a nasal antibiotic cream called mupirocin, Manuka honey nasal rinses, or budesonide nasal rinses.

Who may not be able to join:

  • You have nasal polyps (small growths inside the nose).
  • You have an existing autoimmune condition (where your immune system attacks your own body).
  • You have a known allergy to silver.
  • You have diabetes.
  • You have previously used colloidal silver (a silver-based natural remedy).
  • You are pregnant, trying to become pregnant, or currently breastfeeding.
  • You are under 18 years of age.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Completed
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
10 December 2015
Est. completion
6 March 2016

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Change in Sino-nasal Outcome Test-22 Score Between Baseline and 6 Weeks, Then 6 Weeks to 12 Weeks.; Change in Endoscopic Lund-Kennedy Score From Baseline to 6 Weeks, Then 6 Weeks to 12 Weeks

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov